300497SZSE
🚨 Material Event

Jiangxi Fuxiang Pharmaceutical Co., Ltd. 2026 Interim Performance Forecast

✨ AI Summary

Jiangxi Fuxiang Pharmaceutical Co., Ltd. forecasts a positive net profit for the first half of 2026, turning losses into gains. Key drivers include increased production and sales of VC electrolyte additive and FEC products, with new energy business becoming a core growth engine. The company also sees steady development in its pharmaceutical manufacturing segment.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300497

Securities Abbreviation: Fuxiang Shares

Announcement Number: 2026-061

Jiangxi Fuxiang Pharmaceutical Co., Ltd.

2026 Interim Performance Forecast

The Company and the Board of Directors guarantee that the information disclosed in this report is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.

I. Performance Forecast for the Current Period

  1. Performance Forecast Period: January 1, 2026, to June 30, 2026.

  2. Performance Forecast: Expected net profit to be positive, turning losses into gains.

ItemReporting PeriodPrior Year Period
Net profit attributable to shareholders of the listed companyProfit: RMB 16,500 million - RMB 21,450 millionLoss: RMB 691.12 million
Year-on-year growth2487% - 3204%
Net profit after deducting non-recurringProfit: RMB 16,100 million - RMB 21,050 millionLoss: RMB 3,217.98 million
gains and losses

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.